CMS’ GLP-1 Bridge Demonstration—Questions and Potential Consequences
JAMA · 28.07.2026 · 336 (4) · 283
DOI: 10.1001/jama.2026.11253 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 28.07.2026. Verfasst von Rachel E Sachs und 1 weiteren Autor:innen. Beteiligte Einrichtung: Washington University in St Louis School of Law, St Louis, Missouri. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
This Viewpoint discusses the US Centers for Medicare & Medicaid Services’ (CMS) extension of the Medicare Glucagon-Like Peptide-1 (GLP-1) Bridge and outlines unanswered questions related to how the bridge will affect Medicare.
Autor:innen und Institutionen
- Washington University in St Louis School of Law, St Louis, Missouri.
- Highway 136 Consulting, Washington, DC.
Zitieren
APA
Sachs, R. E., & Martin, K. (2026). CMS’ GLP-1 Bridge Demonstration—Questions and Potential Consequences. JAMA, 336(4), 283. https://doi.org/10.1001/jama.2026.11253
Vancouver
Sachs RE, Martin K. CMS’ GLP-1 Bridge Demonstration—Questions and Potential Consequences. JAMA. 2026;336(4):283. doi:10.1001/jama.2026.11253
BibTeX
@article{Sachs2026,
author = {Sachs, Rachel E and Martin, Kristi},
title = {CMS’ GLP-1 Bridge Demonstration—Questions and Potential Consequences},
journal = {JAMA},
year = {2026},
volume = {336},
number = {4},
pages = {283},
doi = {10.1001/jama.2026.11253}
}
EUVIMED